Analysts have recently evaluated Charles River and provided 12-month price targets. The average target is $214.5, accompanied by a high estimate of $250.00 and a low estimate of $185.00. A 2.72% drop ...

Fintel reports that on January 22, 2025, William Blair downgraded their outlook for Charles River Laboratories International ...

T-cell immunotherapy company Atara Biotherapeutics closed 8% lower on Tuesday, having lost 41% of its stock market value on ...

Charles River Laboratories International, Inc. CRL has introduced Apollo for CRADL (Charles River Accelerator and Development Lab), a secure cloud-based platform that enhances leading vivarium rental ...

H.C. Wainwright analyst Robert Burns has reiterated their neutral stance on ATRA stock, giving a Hold rating yesterday.Invest with Confidence: ...

Upslope Capital Management, an investment management firm, released its fourth-quarter 2024 investor letter. A copy of the ...

Riverwater Partners, an investment management company, released its “Sustainable Value Strategy” Q4 2024 investor letter. A ...

Atara Biotherapeutics Provides Update on Clinical Programs Related to EBVALLO™ (tabelecleucel) and ATA3219 ...

Equities research analysts at William Blair reduced their FY2025 earnings per share (EPS) estimates for shares of Charles River Laboratories International in a report issued on Wednesday, January 15th ...

Atara Biotherapeutics has just announced a CRL by FDA for EBVALLO. Click here to read more about ATRA stock and why it is ...

UBS Group reaffirmed their neutral rating on shares of Charles River Laboratories International (NYSE:CRL – Free Report) in a research note released on Friday morning, MarketBeat reports. They ...

In recent trading, Charles River Lbrtrs ntrntl Inc (CRL) stock price has shown some volatility, fluctuating -12.15% over the last five trades and -13.98% over the past 30 trades. This represents a ...